Edgewise Therapeutics, Inc. (EWTX) Q3 2025 10-Q Quarterly Report
Edgewise Therapeutics, Inc. (EWTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Edgewise Therapeutics, Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: Initiated Phase 1 trial for EDG-15400 in Sept 2025, expanding clinical development pipeline
- • Material update: Net loss $117.6M YTD Sept 2025, accumulated deficit $496.2M, reflecting increased R&D and operational expenses
Edgewise Therapeutics, Inc. Q3 2025 Quarterly FinancialsXBRL
Net Income
-$41M
▼ -19.2% YoY▼ -12.6% QoQ
ROE
-7.3%
Total Assets
$583M
EPS (Diluted)
$-0.38
▼ -2.7% YoY▼ -11.8% QoQ
Operating Cash Flow
-$35M
▼ -27.0% YoY▼ -6.7% QoQ
Source: XBRL data from Edgewise Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Edgewise Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.